SynthesisNeurology2014
Assessing treatment response to interferon-β: is there a role for MRI?
Synthesis in Neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 64 citations in OpenAlex.
- Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2019Trial
- Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.Neurology · 2019Trial
- Trial
- Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.BMC neurology · 2016Trial
- Evaluating the Impact of Teriflunomide and Dimethyl Fumarate on Quality of Life in Relapsing-remitting Multiple Sclerosis: Insights from Eastern Saudi Arabia.Annals of African medicine · 2025Article
- Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review].Neurology and therapy · 2023Review
- Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.Systematic reviews · 2022Article
- Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.AJNR. American journal of neuroradiology · 2017Review
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients.BMC neurology · 2017Article
- Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.The pharmacogenomics journal · 2017Article
- Defining Disease Activity and Response to Therapy in MS.Current treatment options in neurology · 2017Review
- Outcome Measures in Clinical Trials for Multiple Sclerosis.CNS drugs · 2017Review
- Treatment decisions in multiple sclerosis - insights from real-world observational studies.Nature reviews. Neurology · 2017Review
- Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.PloS one · 2017Observational
- MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: a retrospective analysis of a community based cohort.BMC neurology · 2016Article
- Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach.BMC neurology · 2016Review
- Improved Lesion Detection by Using Axial T2-Weighted MRI with Full Spinal Cord Coverage in Multiple Sclerosis.AJNR. American journal of neuroradiology · 2016Article
- Predictors of disease activity in 857 patients with MS treated with interferon beta-1b.Journal of neurology · 2015Article
- Newer therapies for multiple sclerosis.Annals of Indian Academy of Neurology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInterferon-β (IFN-β) has been shown to reduce relapse rates in multiple sclerosis; however, the clinical response appears to vary among individuals. Can early MRI be used to identify those patients who have a poor response to treatment?
methodsA systematic review of studies examining differential treatment response and clinical endpoints in groups defined as responders or nonresponders to IFN-β was performed. Meta-analytic techniques were used to combine study results where appropriate.
resultsPatients with MRI evidence of poor response to IFN-β treatment as defined by either ≥2 new hyperintense T2 lesions or new gadolinium-enhancing lesions had significantly increased risk of both future relapses and progression as defined by the Expanded Disability Status Scale. There appeared to be an increased risk of poor outcomes 16 years after treatment initiation in those with an initial poor response to treatment. Previous evidence has shown this not to be the case in placebo arms of clinical trials.
conclusionsFor those patients starting IFN-β, early MRI, within 6 to 24 months after starting treatment, has the potential to provide important information when counseling patients about the likelihood of future treatment failure. This can inform treatment decisions before clinical relapses or disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.